- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02905253
A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects
6 de julio de 2018 actualizado por: Idorsia Pharmaceuticals Ltd.
A Three-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of AC-084 in Healthy Subjects and to Investigate the Pharmacokinetics of a Single Dose of AC-084 in Healthy CYP2C9 Poor Metabolizers
The primary purpose of this first-in-man study is to investigate whether AC-084 is safe and well-tolerated when orally administered at single- and multiple-ascending dose to healthy adults
Descripción general del estudio
Descripción detallada
The study is designed in three parts, A, B and C
Part A: single-center, double-blind, randomized, placebo-controlled, single ascending dose
Part B: single-center, double-blind, randomized, placebo-controlled, multiple ascending dose
Part C: single-center, open-label, single dose in CYP2C9 poor metabolizers
Tipo de estudio
Intervencionista
Inscripción (Actual)
56
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Leeds, Reino Unido, LS2 9LH
- Covance Clinical Research Unit
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 55 años (Adulto)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Signed informed consent in the local language prior to any study-mandated procedure
- Healthy male subjects for Part A, healthy male and female subjects for Part B and Part C aged between 18 and 55 years (inclusive) at screening
- No clinically significant findings on physical examination at screening
- Body mass index (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at screening
- CYP2C9 poor metabolizers (Part C)
Exclusion Criteria:
- History or clinical evidence of any disease and/or existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed)
- Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions
- Treatment or substances known to induce CYP enzyme drug metabolism within 30 days prior to first study treatment administration
- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
- Known allergic reactions or hypersensitivity to the study treatment or drugs of the same class, or any of their excipients
- For Part A and Part B, CYP2C9 poor metabolizers enrolled in a cohort to be dosed with single or multiple dose of 500 mg or higher of ACT-774312 (confirmed by genotyping before enrollment)
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: AC-084, single ascending dose (Part A)
AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort).
Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
|
Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
|
|
Comparador de placebos: Placebo,single ascending dose (Part A)
Matched placebo administered as single ascending doses in parallel to AC-084
|
Placebo capsules matching AC-084 capsules
|
|
Experimental: AC-084, multiple ascending dose (Part B)
AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels.
The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
|
Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
|
|
Comparador de placebos: Placebo,multiple ascending dose (Part B)
Matched placebo administered as multiple ascending doses in parallel to AC-084
|
Placebo capsules matching AC-084 capsules
|
|
Experimental: AC-084, single dose (Part C)
Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)
|
Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants with adverse events (AEs) (Part A)
Periodo de tiempo: From dosing until day 4
|
Treatment-emergent AEs and treatment-emergent serious AEs
|
From dosing until day 4
|
|
Number of participants with adverse events (AEs) (Part B)
Periodo de tiempo: From dosing until day 8
|
Treatment-emergent AEs and treatment-emergent serious AEs
|
From dosing until day 8
|
|
Number of participants with adverse events (AEs) (Part C)
Periodo de tiempo: From dosing until day 6
|
Treatment-emergent AEs and treatment-emergent serious AEs
|
From dosing until day 6
|
|
Incidence of safety events of interest (Part A)
Periodo de tiempo: From dosing until day 4
|
Events of interest are any abnormalities in ECG, vital signs or laboratory test results
|
From dosing until day 4
|
|
Incidence of safety events of interest (Part B)
Periodo de tiempo: From dosing until day 8
|
Events of interest are any abnormalities in ECG, vital signs or laboratory test results
|
From dosing until day 8
|
|
Incidence of safety events of interest (Part C)
Periodo de tiempo: From dosing until day 6
|
Events of interest are any abnormalities in ECG, vital signs or laboratory test results
|
From dosing until day 6
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximum plasma concentration (Cmax) following single oral ascending doses (Part A)
Periodo de tiempo: From dosing until day 4
|
Cmax is derived from the observed plasma concentration-time curves
|
From dosing until day 4
|
|
Maximum plasma concentration (Cmax) following single oral ascending doses (Part B)
Periodo de tiempo: From dosing until day 8
|
Cmax is derived from the observed plasma concentration-time curves
|
From dosing until day 8
|
|
Maximum plasma concentration (Cmax) following single oral ascending doses (Part C)
Periodo de tiempo: From dosing until day 6
|
Cmax is derived from the observed plasma concentration-time curves
|
From dosing until day 6
|
|
Time to reach Cmax (tmax) following single oral ascending doses (Part A)
Periodo de tiempo: From dosing until day 4
|
Tmax is derived from the observed plasma concentration-time curves
|
From dosing until day 4
|
|
Time to reach Cmax (tmax) following single oral ascending doses (Part B)
Periodo de tiempo: From dosing until day 8
|
Tmax is derived from the observed plasma concentration-time curves
|
From dosing until day 8
|
|
Time to reach Cmax (tmax) following single oral ascending doses (Part C)
Periodo de tiempo: From dosing until day 6
|
Tmax is derived from the observed plasma concentration-time curves
|
From dosing until day 6
|
|
Terminal half-life [t(1/2)] following single oral ascending doses (Part A)
Periodo de tiempo: From dosing until day 4
|
From dosing until day 4
|
|
|
Terminal half-life [t(1/2)] following single oral ascending doses (Part B)
Periodo de tiempo: From dosing until day 8
|
From dosing until day 8
|
|
|
Terminal half-life [t(1/2)] following single oral ascending doses (Part C)
Periodo de tiempo: From dosing until day 6
|
From dosing until day 6
|
|
|
Area under the plasma concentration-time curve (AUC) following single oral ascending doses (Part A)
Periodo de tiempo: From dosing until day 4
|
AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity
|
From dosing until day 4
|
|
Area under the plasma concentration-time curve (AUC) following single oral ascending doses (Part B)
Periodo de tiempo: From dosing until day 8
|
AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity
|
From dosing until day 8
|
|
Area under the plasma concentration-time curve (AUC) following single oral ascending doses (Part C)
Periodo de tiempo: From dosing until day 6
|
AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity
|
From dosing until day 6
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Director de estudio: Martine Géhin, PhD, Actelion
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
12 de septiembre de 2016
Finalización primaria (Actual)
10 de diciembre de 2017
Finalización del estudio (Actual)
10 de diciembre de 2017
Fechas de registro del estudio
Enviado por primera vez
31 de agosto de 2016
Primero enviado que cumplió con los criterios de control de calidad
14 de septiembre de 2016
Publicado por primera vez (Estimar)
19 de septiembre de 2016
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
10 de julio de 2018
Última actualización enviada que cumplió con los criterios de control de calidad
6 de julio de 2018
Última verificación
1 de julio de 2018
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- AC-084-101
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .